Novel Receptor Based Bioassay for Quantitative Detection of Gallium in Tumors and Therapeutic Imaging

A bioassay method developed for the determination of nano gram and sub-nano gram levels of gallium in blood, tissues, and other biological materials is described. The detection of gallium in biological samples is used in the diagnosis of tumors and the treatment of cancer. The disclosed method is based upon the selectivity of a chelating reagent coupled with proteins to produce a conjugate. The resulting conjugate is then used in an immunoassay format for the quantitative detection of gallium. The analytical sensitivity of the assay is in parts per billion range with a standard deviation of less than five percent. The selectivity of the assay was tested under routine clinical conditions in combination with over 30 metal ions with no observable interference. The methodology requires no prior extraction or back extraction prior to assay, and is not subject to matrix interference associated with current instrumental techniques.

Advantages:

The technology provides a rapid, low cost means for gallium detection with substantially improved selectivity for gallium relative to existing instrumentation methods. Also, the methodology displays no sodium or potassium interference and requires no extraction of samples prior to analysis.

Intellectual Property:

U.S. 6,602,989

 

Binghamton University RB123

Patent Information:
Technology/Start-up ID: